Inside the Compounding Industry's Legal Challenge to FDA Shortage Resolutions
Trade groups representing compounding pharmacies have challenged the FDA's decision to resolve semaglutide and tirzepatide shortages in court.
By the GLP Semaglutide editorial team · Last updated December 15, 2025
Compounding pharmacy trade associations have pursued legal challenges arguing that the FDA's process for resolving semaglutide and tirzepatide shortage designations didn't adequately account for continued spot shortages or regional supply gaps.
What's actually being litigated
These cases generally center on administrative law questions — whether the FDA followed its own procedures and evidentiary standards in declaring a shortage resolved — rather than disputing the underlying safety concerns the FDA has raised about compounded GLP-1 products.
Why the outcome matters
A court ruling in either direction would directly affect whether large-scale compounding of semaglutide or tirzepatide can legally continue, making this litigation worth tracking through primary legal filings rather than characterizations in secondary coverage.
Primary sources